Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuyanxiao is a Traditional Chinese Medicine (TCM) formulation, typically administered as a capsule, used for the treatment of gynecological inflammatory conditions, specifically pelvic inflammatory disease (PID) characterized by damp-heat stasis syndrome. Developed by Dongfang Hospital of the Beijing University of Chinese Medicine, it is often evaluated as an adjunctive therapy combined with standard antibiotics to improve clinical outcomes and reduce recurrence rates. The formulation is designed according to TCM principles to clear heat, detoxify the body, and promote blood circulation to resolve stasis, thereby addressing the underlying pathology of chronic pelvic inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuyanxiao.